

# Pharmacia & Upjohn

Agent ID# 43526

## DEPO-MEDROL® Sterile Aqueous Suspension MATERIAL SAFETY DATA SHEET

### 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

**COMMON NAME:** DEPO-MEDROL® Sterile Aqueous Suspension (Animal Health Product)  
**SYNONYMS:** 468227 – EDP Number; 468228 – EDP Number; 468391 – EDP Number  
**MOLECULAR FORMULA:** Mixture  
**USE:** Veterinary drug for the treatment of inflammatory and allergic conditions in dogs and cats and for the alleviation of pain and lameness associated with acute localized or general arthritic conditions in horses. Not for human use.  
**MANUFACTURER/SUPPLIER:**  
 PHARMACIA & UPJOHN CO., A SUBSIDIARY OF PHARMACIA CORP.  
 7171 PORTAGE RD  
 KALAMAZOO, MI 49001-0199  
**TELEPHONE NUMBERS:**  
 (616) 833-5122 - (24 Hours)  
 (616) 833-7555 - (8:00 AM - 4:30 PM, EST)

### 2. COMPOSITION/INFORMATION ON INGREDIENTS

#### INGREDIENT 1

**COMMON NAME:** Water.  
**% BY WEIGHT:** 91% to 93%  
**CAS NUMBER:** 7732-18-5  
**EXPOSURE LIMIT(S):** Not established.

#### INGREDIENT 2

**COMMON NAME:** Carbowax™ Polyethylene Glycol 3350.  
**% BY WEIGHT:** 3 %  
**EXPOSURE LIMIT(S):** Not established.

#### INGREDIENT 3

**COMMON NAME:** Non-hazardous Ingredient(s).  
**% BY WEIGHT:** 2 %  
**EXPOSURE LIMIT(S):** Not established.

#### INGREDIENT 4

**COMMON NAME:** Methylprednisolone Acetate.  
**CHEMICAL NAME:** Pregna-1,4-diene-3,20-dione, 21-(acetyl-oxy)-11,17-dihydroxy-6-methyl-, (6a,11b)-  
**% BY WEIGHT:** 2% to 4%  
**CAS NUMBER:** 53-36-1  
**EXPOSURE LIMIT(S):**  
 PHARMACIA & UPJOHN EXPOSURE LIMIT-TWA:  
 4 µg/m<sup>3</sup>  
**SKIN NOTATION:** Yes.

**EXPOSURE LIMIT(S) FOR THE MATERIAL:** Not established.

### 3. HAZARDS IDENTIFICATION

**PRIMARY ROUTE(S) OF EXPOSURE:** Skin contact, eye contact, ingestion, and inhalation.

**EFFECTS OF OVEREXPOSURE:** Methylprednisolone acetate is a glucocorticosteroid. Glucocorticoids affect carbohydrate, protein and fat metabolism; functions of the cardiovascular system, kidney, skeletal muscle, nervous system and other organs and tissues; and may modify the body's immune responses to diverse stimuli. Chronic overexposure to glucocorticoids may produce pituitary-adrenal suppression, Cushing's syndrome [redistribution of body fat to face ("moon face"), back of neck and trunk], increased susceptibility to infections (suppression of inflammatory response), osteoporosis, cataracts, glaucoma with possible damage to optic nerve, mental symptoms, hyperglycemia and glycosuria, muscular weakness and fatigue, acne, menstrual disorders and peptic ulcers. Naturally occurring glucocorticoids (such as hydrocortisone and cortisone), in average and large doses, may cause elevation of blood pressure, salt and water retention, and increased potassium excretion. These effects are less likely to occur with methylprednisolone acetate except in large doses. All corticosteroids increase calcium excretion.

#### MEDICAL CONDITIONS AGGRAVATED BY

**EXPOSURE:** Overexposure to corticosteroids may increase susceptibility to infection (including reactivation of latent tuberculosis and enhancement of secondary eye infections due to fungi or viruses) or mask some signs of infection. Recent immunization procedures may result in a lack of antibody response and neurological disorders. Hypersensitivity to this material may result. Corticosteroids exhibit enhanced effects on persons with hypothyroidism or cirrhosis.

### 4. FIRST AID MEASURES

**EYES:** Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes.

**SKIN:** Wash off with soap and water. Take off all contaminated clothing immediately.

**INHALATION:** Move to fresh air.

**INGESTION:** Contact a physician or poison control center.

### 5. FIRE FIGHTING MEASURES

**FLASH POINT:** Nonflammable.

**LOWER EXPLOSION LIMIT (LEL):** Not applicable.

**UPPER EXPLOSION LIMIT (UEL):** Not applicable.

**EXTINGUISHING MEDIA:** Water, carbon dioxide or dry chemical.

**FIRE FIGHTING PROCEDURES:** Wear self-contained breathing apparatus and full-body protective equipment.

# Pharmacia & Upjohn

Agent ID# 43526

## DEPO-MEDROL® Sterile Aqueous Suspension MATERIAL SAFETY DATA SHEET

**UNUSUAL FIRE OR EXPLOSION HAZARDS:** None known.

**HAZARDOUS COMBUSTION PRODUCTS:** Carbon monoxide. Carbon dioxide.

### 6. ACCIDENTAL RELEASE MEASURES

#### STEPS TO BE TAKEN IN CASE MATERIAL IS

**RELEASED OR SPILLED:** Control the generation of vapors; provide adequate ventilation and respiratory, skin and eye protection to prevent overexposure. Keep out of drains; prevent entry to surface water, groundwater and soil. Vacuum or scoop spilled material and place in container.

### 7. HANDLING AND STORAGE

#### PRECAUTIONS FOR HANDLING AND STORING:

Avoid contact with skin, eyes and clothing. Wash thoroughly after handling. Launder contaminated clothing before use. Store in a cool, dry place. Protect from light. Keep out of reach of children.

### 8. EXPOSURE CONTROLS/ PERSONAL PROTECTION

**RESPIRATORY PROTECTION:** Not required.

**VENTILATION:** Local exhaust.

**PROTECTIVE GLOVES:** Not required.

**EYE PROTECTION:** Not required.

**OTHER PROTECTIVE EQUIPMENT:** Not required.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

**APPEARANCE/PHYSICAL STATE:** Aqueous solution.

**MOLECULAR WEIGHT:** Mixture.

### 10. STABILITY AND REACTIVITY

**STABILITY:** Stable at normal conditions.

**PHYSICAL CONDITIONS TO AVOID:** None.

**INCOMPATIBILITY WITH OTHER MATERIALS:** None.

**HAZARDOUS DECOMPOSITION PRODUCTS:** None.

**HAZARDOUS POLYMERIZATION:** Does not occur.

### 11. TOXICOLOGICAL INFORMATION

**ACUTE STUDIES:** The following data applies to the active ingredient methylprednisolone acetate.

**EYE IRRITATION (RABBIT):** Non-irritating.

**SKIN IRRITATION (RABBIT):** Non-irritating to intact or abraded skin.

**SENSITIZATION:** No information found.

**ORAL LD50 (RAT):** >10 g/kg (not acutely toxic)

**INTRAPERITONEAL LD50 (MOUSE):** >1,409 mg/kg

#### OTHER STUDIES:

**GENOTOXICITY:** Mutagenicity: Methylprednisolone was negative in the DNA damage/alkaline elution assay.

**TERATOGENICITY:** Corticosteroids are generally teratogenic in laboratory animals when administered systemically, but there are no well-controlled studies in women. The safety of their use in pregnant women has not been absolutely established.

**CARCINOGENICITY:** Methylprednisolone was negative in the DNA-cell-binding assay. Not listed as a carcinogen by IARC, NTP or OSHA.

### 12. DISPOSAL CONSIDERATIONS

**WASTE DISPOSAL METHOD:** Dispose of by incineration in accordance with applicable international, national, state, and/or local waste disposal regulations.

### 13. SHIPPING REGULATIONS

Not regulated for transportation by the United States Department of Transportation (DOT), International Maritime Organization (IMO), or International Air Transport Association (IATA). May be subject to state and/or local transportation requirements.

### 14. OTHER INFORMATION

**REVIEWED BY:** Environment & Safety

**DISCLAIMER:** The information contained in the MSDS is believed to be correct as of its date of issuance. BY MAKING THE MSDS AVAILABLE, PHARMACIA & UPJOHN CO. DOES NOT MAKE ANY EXPRESS OR IMPLIED WARRANTY (INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE) REGARDING THE MSDS, ITS ACCURACY OR THE PRODUCT TO WHICH IT RELATES. Anyone using this information agrees that Pharmacia & Upjohn shall not be held liable (based on its negligence or otherwise) for any personal injury or other damage relating to, or arising from such use, including direct, incidental, or consequential damage and such user agrees to indemnify Pharmacia & Upjohn for any claims arising out of its use.

Agent ID# 43526

## 15. LABELING

This drug is subject to FDA labeling requirements; therefore, it is exempt from the labeling requirements of the OSHA Hazard Communication Standard.

NDC 0009-0613-01  
NDC 0009-0613-04  
NDC 0009-0614-01

*July 31, 2001*